A novel NMDA receptor glycine-site partial agonist, GLYX-13, has therapeutic potential for the treatment of autism.

@article{Moskal2011ANN,
  title={A novel NMDA receptor glycine-site partial agonist, GLYX-13, has therapeutic potential for the treatment of autism.},
  author={Joseph r. Moskal and Jeffrey S. Burgdorf and Roger A. Kroes and Stefan M. Brudzynski and Jaak Panksepp},
  journal={Neuroscience and biobehavioral reviews},
  year={2011},
  volume={35 9},
  pages={1982-8}
}
Deficits in social approach behavior, rough-and-tumble play, and speech abnormalities are core features of autism that can be modeled in laboratory rats. Human twin studies show that autism has a strong genetic component, and a recent review has identified 99 genes that are dysregulated in human autism. Bioinformatic analysis of these 99 genes identified the NMDA receptor complex as a significant interaction hub based on protein-protein interactions. The NMDA receptor glycine site partial… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 5 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 33 extracted citations

Effects of sarcosine and N, N-dimethylglycine on NMDA receptor-mediated excitatory field potentials

Journal of Biomedical Science • 2016
View 5 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…